Ask an Anaesthetist

More videos


Q1. Can recurarization occur with Sugammadex?

Dr. Guy Cammu breaks down why it’s critical to continually monitor patients when administering Sugammadex and the risk of recurarization and residual paralysis even after dosage. He presents compelling case studies and references to recent research, including works by Ledowski and Amit Raval, which demonstrate the potential for residual neuromuscular blockade incidents.

Product Guides


Connect STIMPOD to a Philips patient monitor

The Stimpod NMS450X TOF Monitor (NMT Monitor) can connect to a Philips patient monitor to integrate neuromuscular transmission data with other patient information. This guide will teach you to do this.

Clinical Education


Train of Four monitoring in the ICU

In this video you will learn how to set up the Stimpod NMS450X neuromuscular monitor (TOF Monitor) for use in the ICU.



Webinar Neuromuscular Block Monitoring with Prof Heidrun Lewald and Dr Grant Rodney

Risk of Residual Neuromuscular Blockade and Enhancing Clinical Practice using NMT Monitoring. Prof Heidrun Lewald and Dr Grant Rodney explains the risks of residual neuromuscular blockade and why it is important to continuously monitor, regardless of whether sugammadex and/or neostigmine is used. Learn how to enhance you practice through quantitative TOF (Train of Four) monitoring with either AMG or EMG using the ulnar nerve, tibial nerve and/or facial nerve.



“Behind the Mask” 1:1 Interview with Dr Grant Rodney and Objective Neuromuscular Block monitoring

Dr. Rodney explains how despite advances in paralytic agents and reversal drugs like sugammadex, the problem of residual neuromuscular blockade has not yet been solved, with studies showing it occurs in 30-40% of cases without quantitative monitoring. He highlights how recent guidelines from ASA, ESAIC, and other major anesthesia societies all definitively recommend quantitative train-of-four ratio monitoring for all cases involving neuromuscular blocking agents Dr. Rodney emphasizes how quantitative monitoring, proper paralytic dosing, appropriate reversal agent selection, and targeting a train-of-four ratio at least 0.9 all play a key role in improving patient safety and outcomes.